The company said, “The company is affirming its guidance for the approximately seven-month transition period from May 26 through December 31, 2025. For this transition period, the company expects revenue to be approximately $74 to $76 million, net loss is expected to range from $18.4 million to $16.4 million, and Adjusted EBITDA is expected to be in the range of $12 to $14 million, based on the expectation that Lifecore (LFCR) would exclude for items similar to its historic definition of Adjusted EBITDA. This guidance takes into consideration existing market forces, contracts, and customer order timing, as well as the company’s current beliefs and estimations with respect to success and timing related to growing and diversifying the company’s new business development revenue.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Lifecore reports Q3 EPS (29c), consensus (31c)
- Lifecore Biomedical Approves Key Proposals at Annual Meeting
- Lifecore signs agreement with leading global pharmaceutical company
- Lifecore, PolyPeptide collab to offer peptide manufacturing solution
- Lifecore Biomedical, Inc. (LFCR) Q1 Earnings Cheat Sheet